HHS appoints eight new U.S. Preventive Services Task Force members, reshaping the panel’s expertise and raising implementation questions

On September 17, the Department of Health and Human Services (HHS) announced eight new appointments to the U.S. Preventive Services Task Force (USPSTF). The new members will join the eight members currently serving on the Task Force, returning the panel to its customary 16-member size. HHS named Dr. Seth J. Corey, a pediatric hematologist-oncologist and academic physician at Cleveland Clinic and Case Western Reserve University, as chair. No vice chairs were appointed.

The appointments follow a prolonged period of uncertainty for the USPSTF. The Task Force has not convened since March 2025, with multiple scheduled meetings canceled since then.  The Task Force’s composition is expected to continue to evolve, with three current members’ terms set to expire at the end of 2026.

For life sciences companies and health plans, the USPSTF’s ability to resume its work—and potential new approaches to evidence review with its new members—will be consequential. The Task Force’s recommendations influence preventive care practice, clinical quality strategies, and, most notably, health plan preventive service coverage requirements.

USPSTF recommendations have direct implications for coverage

The USPSTF is an independent volunteer panel that reviews evidence and issues recommendations on clinical preventive services delivered in primary care settings, including screening tests, behavioral counseling interventions, and preventive medications. USPSTF recommendations assess the certainty and magnitude of a service’s net benefit by weighing its potential benefits and harms in specified populations.

Under the Affordable Care Act (ACA), most non-grandfathered private health plans must cover in-network preventive services that receive an A or B grade from the USPSTF without patient cost sharing, subject to applicable statutory and regulatory requirements. As a result, changes in USPSTF recommendations can affect benefit design, coverage policies, provider communications, utilization management approaches, member outreach, and demand for preventive services.

More specialists and fewer primary care physicians in new USPTF member roster

Historically, the USPSTF was composed primarily of clinicians with backgrounds in primary care and prevention. This reflected the Task Force’s role in developing recommendations for services delivered in, or referred from, primary care settings. When reviewing topics requiring specialized clinical expertise, the USPSTF traditionally sought input from specialty experts and professional societies as part of its evidence review and public comment processes.

The new appointees include two cardiologists, a gastroenterologist, a radiologist, a pediatric hematologist-oncologist, and a health finance professor. Of the eight newly appointed members, only two—pediatrician Patrick K. Hunter and family medicine physician Goldie Stands-Over-Bull—are primary care clinicians.

The American Medical Association (AMA) characterized the new slate as a “significant departure” from the Task Force’s traditional composition. In a September 17 statement, AMA President Dr. Willie Underwood III emphasized that the Task Force’s credibility has been grounded in prevention and primary care, and urged HHS to maintain a strong primary care perspective in its work.

Other organizations have viewed the increased specialty representation more favorably. The American College of Radiology praised the appointment of diagnostic radiologist Dennis W. Wulfeck, stating that Dr. Wulfeck “brings a wealth of experience and expertise to the role” and welcomed the inclusion of a radiologist on the Task Force.

These contrasting responses reflect a central question for stakeholders: Will a broader mix of clinical specialties strengthen the panel’s ability to evaluate rapidly evolving preventive interventions, or make it harder to sustain the primary care orientation that has historically defined USPSTF recommendations?

Appointment of a health finance expert may renew attention to cost considerations

One especially notable appointment is Dr. Stephen T. Parente, a professor of health finance at the University of Minnesota who previously held health policy roles in the first Trump administration. HHS stated that Dr. Parente was selected for his expertise in “evaluating the cost and value of healthcare services and technologies and their impacts on patients and the delivery of care.”

The appointment has drawn attention because the USPSTF has historically excluded cost as a consideration from its recommendation grades. The Task Force’s policy on the subject states:

“While the Task Force has congressional authority to review evidence related to cost-effectiveness, it excludes costs from its determination of the benefits and harms of a clinical preventive service. This deliberate decision was made to maintain a clear focus on the science of clinical effectiveness … and not consider cost, in part to avoid any misperception that the Task Force’s purpose is to limit health care based on cost.”

Under the Task Force’s current procedures, recommendation grades are based solely on evidence regarding clinical benefits, harms, and the certainty and magnitude of net benefit. Task Force procedures allow the group to provide contextual information on costs, including cost effectiveness studies, but state that financial cost is not part of the benefit-harm determination.

HHS has not announced a change to this methodology. Nonetheless, Dr. Parente’s appointment may prompt stakeholders to monitor whether future USPSTF recommendations place greater emphasis on value, affordability, feasibility, or delivery system implications.

Leadership and conflict-of-interest transparency will be closely watched

Dr. Corey’s appointment as chair is also a departure from precedent. Unlike prior chairs, who generally had first served on the Task Force, Dr. Corey assumes the role as a new appointee. Reporting has also noted that his public social media activity over the last several years has expressed support for Secretary Robert F. Kennedy Jr. and criticism of COVID-19 vaccine policies and the federal pandemic response.

Stakeholders have raised concerns about potential conflicts of interest associated with specialty representation. Specialty clinicians may have deep subject matter expertise in particular screening and treatment pathways, but may also practice in areas that could experience increased demand if the Task Force recommends additional screening or diagnostic services. The Task Force’s longstanding conflict-of-interest procedures are designed to identify and manage financial and non-financial conflicts, including potential restrictions on participation in particular topic workgroups or votes.

The publicly available USPSTF conflict-of-interest disclosure page currently identifies disclosures as current only through March 2025 and primarily lists former or pre-appointment members. It does not yet provide current disclosures for the newly announced members. Given the new appointments and heightened external scrutiny, prompt publication of updated member disclosures and related management actions would support transparency and stakeholder confidence in future USPSTF recommendations.

Implications for life sciences companies and health plans

The new appointments do not change existing USPSTF recommendations or ACA preventive service coverage obligations. However, they do signal that the Task Force will likely soon resume consideration of delayed and emerging prevention topics, although perhaps with changes in both philosophical viewpoints and actual revisions to the USPSTF procedure manual.

Life sciences organizations should monitor the USPSTF’s research plans, evidence reviews, draft recommendations, and public comment periods. Developers of screening technologies, diagnostics, preventive medicines, and digital prevention tools should ensure that evidence generation strategies address the outcomes central to USPSTF review: patient-centered clinical benefits, potential harms, test performance, downstream care pathways, and applicability across intended populations.

Health plans should prepare for the potential release of delayed recommendations and for a more active USPSTF agenda. This includes maintaining processes to assess coverage requirements, benefit configuration, coding, provider-network capacity, member communications, and implementation timelines once final A or B recommendations are issued. USPSTF last shared a recommendation update in August 2025, with four topics pending final recommendation statements.

As the Task Force resumes activity under new leadership and a substantially different membership profile, transparency, methodological consistency, and implementation relevance will be central to maintaining trust in its recommendations.

Avalere Health’s dedicated USPSTF expert team is available to discuss what the new appointments could mean for your organization’s strategy.  To discuss this or learn more about the new appointees, connect with us.